Position in SLS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$0
+$0 QoQ
Shares Held
0
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
5 quarters on record
Derivatives in SLS
reported options exposure · as of Jun 30, 2026CallValue
$5,904,000
CallShares
400,000
PutValue
$1,476,000
PutShares
100,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026DIADEMA PARTNERS LP holds $217,374,297 across 66 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
139,218 | $26,072,747 | |
| 2 | ABVX |
Abivax S.A.
|
163,644 | $21,807,199 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
493,664 | $19,104,796 | |
| 4 | BMRN |
Biomarin Pharmaceutical Inc
|
312,846 | $17,901,048 | |
| 5 | VKTX |
Viking Therapeutics, Inc.
|
441,808 | $17,234,930 | |
| 6 | EWTX |
Edgewise Therapeutics, Inc.
|
272,214 | $11,060,054 | |
| 7 | KOD |
Kodiak Sciences Inc.
|
218,117 | $8,497,838 | |
| 8 | IMCR |
Immunocore Holdings plc
|
254,863 | $8,091,900 |
All Filings in SLS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $5,904,000 | 400,000 | Call | Sole | 2026-08-14 | |
| 2026-06-30 | $1,476,000 | 100,000 | Put | Sole | 2026-08-14 | |
| 2026-03-31 | $1,269,000 | 300,000 | Call | Sole | 2026-05-15 | |
| 2025-12-31 | $1,601,873 | 424,900 | Call | Sole | 2026-02-17 | |
| 2025-09-30 | $644,000 | 400,000 | Call | Sole | 2025-11-14 | |
| 2025-06-30 | $876,000 | 400,000 | Call | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||